Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial

  • Castells, Antoni
  • Quintero, Enrique
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Cubiella, Joaquín
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Akiko, Ono
  • Serra-Burriel, Miquel
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
  • Almazán, Raquel
  • Alonso-Abreu, Inmaculada
  • Banales, Jesús M.
  • Hernández, Vicent
  • Portillo, Isabel
  • Vanaclocha-Espí, Mercedes
  • Vega, Mariola de la
  • COLONPREV study investigators
Background: Colonoscopy and the faecal immunochemical test are accepted strategies for colorectal cancer screening in the average-risk population (ie, people aged ≥50 years without personal or family history of colorectal cancer). In this trial, we aimed to compare whether invitation to screening with faecal immunochemical test was non-inferior to colonoscopy in a screening programme. Methods: COLONPREV was a pragmatic, randomised, controlled, non-inferiority trial done at 15 tertiary hospitals across eight regions of Spain. Eligible participants were presumptively healthy and aged between 50 years and 69 years without a personal history of colorectal cancer, adenoma or inflammatory bowel disease, family history of hereditary or familial colorectal cancer (ie, two or more first-degree relatives with colorectal cancer or one diagnosed before age 60 years), severe comorbidities, or previous colectomy. Participants were randomly assigned (1:1) to one-time colonoscopy or biennial faecal immunochemical test before invitation to screening. The primary endpoint was colorectal cancer mortality at 10 years, assessed in the intention-to-screen population. An absolute difference of less than 0·16 percentage points was required to show non-inferiority. This trial was registered with ClinicalTrials.gov, NCT00906997. Findings: Between June 1, 2009, and Dec 31, 2021, 57 404 individuals were randomly assigned to receive an invitation for colonoscopy (n=28 708) or the faecal immunochemical test (n=28 696). The intention-to-screen population consisted of 26 332 individuals in the colonoscopy group and 26 719 in the faecal immunochemical test group. In the intention-to-screen population, participation in any form of screening was 31·8% in the colonoscopy group and 39·9% in the faecal immunochemical test group (risk ratio [RR] 0·79 [95% CI 0·77 to 0·82]). Faecal immunochemical testing was non-inferior to colonoscopy with regard to the risk of colorectal cancer mortality at 10 years: the risk was 0·22% (55 deaths) in the colonoscopy group and 0·24% (60 deaths) in the faecal immunochemical test group (risk difference -0·02 [95% CI -0·10 to 0·06; RR 0·92 [95% CI 0·64 to 1·32]; pnon-inferiority=0·0005). Interpretation: Participation in screening was higher among individuals invited to faecal immunochemical test screening than colonoscopy screening. On the basis of participation observed in this study, a faecal immunochemical test-based programme was non-inferior to a colonoscopy-based programme for colorectal cancer-related mortality.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Sex‐ and Age‐Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post‐Analysis of the COLONPREV Study

  • Castells, Antoni
  • Quintero, Enrique
  • Serra-Burriel, Miquel
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Cubiella, Joaquín
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Ono, Akiko
  • Coll-Vinent, Blanca
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
Background. Colorectal cancer (CRC) screening is effective and cost-effective in average-risk individuals. The COLONPREV study recently showed that individuals invited to a faecal immunochemical test (FIT) were more likely to participate in screening than those invited to colonoscopy, and that FIT-based screening was non-inferior to colonoscopy with respect to CRC-related mortality and CRC incidence. Objective. To assess whether the outcomes of colonoscopy- and FIT-based screening differ according to sex and age in the invited population. Methods. Presumptively healthy men and women aged 50–69 years were randomised to either a one-time screening colonoscopy or biennial FIT. In this analysis, we report participation and crossover rates, CRC-related mortality, CRC incidence, all-cause mortality, and diagnostic yield for both screening strategies, stratified by sex and by age group (50–59 and 60–69 years). Results. The eligible population consisted of 26,332 individuals assigned to colonoscopy and 26,719 assigned to FIT. As expected, participation and crossover rates were higher in women than in men and in older individuals compared with younger individuals. Participation was also consistently higher in those invited to FIT screening than in those assigned to colonoscopy across both sexes and age groups. The observed reductions in CRC-related mortality and CRC incidence, which were consistent across both screening strategies, were independent of sex or age. However, CRC-related mortality, all-cause mortality, and CRC incidence remained higher in men and older participants than in women and younger participants. Colonoscopy screening showed a higher diagnostic yield of premalignant precursor lesions across all demographic subgroups. Conclusion. Participation and reductions in CRC-related mortality and incidence were consistent across sex and age groups for both FIT- and colonoscopy-based screening strategies. The higher baseline risk observed in men could not be fully mitigated by screening. Trial Registration. ClinicalTrials.gov: NCT00906997
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial

  • Cubiella, Joaquín
  • García-Benito, Carme
  • Castells, Antoni
  • Quintero, Enrique
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Ono, Akiko
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
  • Regueiro-Expósito, Cristina
  • Davila-Piñón, Pedro
  • Diez-Martín, Astrid
Background: The risk of colorectal cancer (CRC) after serrated polyp resection remains unclear, and current surveillance recommendations rely on limited evidence. We evaluated CRC incidence in individuals with advanced serrated lesions (ASL) detected at baseline colonoscopy and compared risk according to the most advanced lesion identified. Methods: Participants undergoing colonoscopy within the COLONPREV trial (n = 8989) were included in this post hoc analysis. Individuals were classified according to the most advanced baseline lesion: no lesion, non-advanced adenoma, advanced adenoma, or ASL. The primary outcome was incident CRC. Cumulative incidence and hazard ratios (HR) were estimated using Cox proportional hazard models. Results: At baseline colonoscopy, serrated polyps were detected in 19.8% of participants, including ASL in 2.5%. Over a mean follow-up of 9.5 years, 44 CRC cases were diagnosed (cumulative incidence 0.49%; incidence rate 0.52 per 1000 person-years). The 10-year cumulative incidence was 0.27% in individuals without baseline lesions (n = 5496), 0.57% in those with non-advanced adenomas (n = 2091), 1.23% in advanced adenomas (n = 1218), and 1.09% in ASL (n = 184). In multivariable analysis, CRC risk was increased for non-advanced adenomas (HR 3.25, 95% CI 1.48–7.16), advanced adenomas (HR 9.77, 95% CI 4.24–22.50), and ASL (HR 6.37, 95% CI 1.42–28.54). Surveillance colonoscopy was associated with lower CRC incidence (HR 0.46, 95% CI 0.22–0.95 for one colonoscopy; HR 0.09, 95% CI 0.02–0.40 for ≥ 2 colonoscopies). Conclusion: In this screening cohort, ASL were associated with increased CRC risk in the range of advanced adenomas. These findings provide risk estimates relevant to post-polypectomy management.